2011 Anniversary Yearbook - EUFEPS today and history
2011 Anniversary Yearbook - EUFEPS today and history
2011 Anniversary Yearbook - EUFEPS today and history
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Network<br />
Environment <strong>and</strong> Pharmaceuticals<br />
European Federation for Pharmaceutical Sciences<br />
Scope <strong>and</strong> Aim<br />
Pharmaceuticals are indispensable for a high quality of life. Their use however also has an<br />
environmental downside that needs to be h<strong>and</strong>led. In recent years, a huge amount of data<br />
has been collected, demonstrating the widespread of a variety of active drug ingredients in<br />
the aquatic environment <strong>and</strong> sporadically even in drinking water. Being only insufficiently<br />
eliminated in the conventional sewage treatment plants, there is growing evidence that the<br />
substances <strong>and</strong> their metabolites have adverse effects on aquatic <strong>and</strong> in some cases terrestrial<br />
organisms on both the individual <strong>and</strong> population level. How to adequately address<br />
these issues? The Network has been initiated to address scientific achievements <strong>and</strong> discuss<br />
various issues on exposure of pharmaceuticals to the environment, including attempts<br />
towards global harmonisation.<br />
Contact Point<br />
Lennart Dencker lennart.dencker@farmbio.uu.se<br />
Network<br />
Food-Drug Synergies<br />
European Federation for Pharmaceutical Sciences<br />
Scope <strong>and</strong> aim<br />
This Network initiative is new. The idea is to assemble the industry-academia-regulatory<br />
triangle to work on topics which cross between food science <strong>and</strong> pharmaceutical sciences.<br />
Topics would be, for example: Personalised nutrition <strong>and</strong> personalised medicine; special<br />
needs (the sick, children, the elderly); sharing technology to evaluate product performance;<br />
best practice to be communicated to public bodies; encouraging liaison across Europe to<br />
create enterprise; <strong>and</strong> to explore new neutraceutical concepts.<br />
Contact point<br />
David Featherston DFE@biopeople.ku.dk<br />
36